Low level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment.
Bernal E, Gómez JM, Jarrín I, et al
 J Acquir Immune Defic Syndr. 2018 Mar 13.
Abstract

Incidence and risk factors for prediabetes and diabetes mellitus among HIV infected adults on antiretroviral therapy: systematic review and meta-analysis.
Nansseu JR, Bigna JJ, Kaze AD, Noubiap JJ.
Epidemiology. 2018 Feb 1.
Abstract

Antiretroviral Therapy in Advanced HIV Disease: Which is the Best Regimen?
Burgos J, Ribera E, Falcó V.
AIDS Rev. 2018 Jan 25;20(1
Abstract

A baseline metabolomic signature is associated with immunological CD4+ T-cell recovery after 36 months of ART in HIV-infected patients.
Rodríguez-Gallego E, Gómez J, et al
AIDS. 2017 Dec 26.
Abstract

FULL-TEXT ARTICLE
A higher CD4/CD8 ratio correlates with an ultralow cell-associated HIV-1 DNA level in chronically infected patients on antiretroviral therapy: a case control study.
Yue Y, Wang N, Han Y,  et al
BMC Infect Dis. 2017 Dec 15;17(1):771.
Paper

Long-term therapeutic impact of the timing of ART in patients diagnosed with primary HIV-1 infection.
Novelli S, Lécuroux C, Avettand-Fenoel V,
Clin Infect Dis. 2017 Dec 2.
Abstract

Predicting CD4 count changes among patients on antiretroviral treatment: Application of data mining techniques.
Kebede M, Zegeye DT, Zeleke BM
Comput Methods Programs Biomed. 2017 Dec;152:
Abstract

Comparing Outcomes of HIV-Infected Chinese Adults on Antiretroviral Therapy by CD4 Count at Treatment Initiation: A Nationwide Retrospective Observational Cohort Study, 2012-2014.
Hu R, Zhang F, Wang V, Dou Z, et al
AIDS Patient Care STDS. 2017
Abstract

I shouldn't talk of medicine only: Biomedical and religious frameworks for understanding antiretroviral therapies, their invention and their effects.
Kelly-Hanku A, Aggleton P, Shih P.
Glob Public Health. 2017 Sep 16:1-14.
Abstract

Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): Immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs.
Tapia G, Højen JF, Ökvist M. et al
J Infect. 2017 Sep 13
bstract

HIV/HAART-associated oxidative stress is detectable by metabonomics.
Williams AA, Sitole LJ, Meyer D.
Mol Biosyst. 2017 Sep 18.
Abstract

Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): Immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs.
Tapia G, Højen JF, Ökvist M, et al
J  Infect. 2017 Sep 13.
Abstract

FULL-TEXT ARTICLE
Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients.
Gianotti N, Poli A, Galli L, Franzin M,  et al
PLoS One. 2017 Aug 1;12(8):e0182007.
Paper

FULL-TEXT ARTICLE
The science of rapid start-From the when to the how of antiretroviral initiation.
Geng EH, Havlir DV.
PLoS Med. 2017 Jul 25;14(7):e1002358.
Paper

The ART Advantage: Health Care Utilization for Diabetes and Hypertension in Rural South Africa.
Manne-Goehler J, Montana L, Gómez-Olivé FX,  et al
J Acquir Immune Defic Syndr. 2017 Aug 15
Abstract

Immune recovery of middle-aged HIV patients following antiretroviral therapy: An observational cohort study.
Wong NS, Chan KCW, Cheung EKH, et al 
Medicine (Baltimore). 2017 Jul;96(28):e7493.
Abstract

FULL-TEXT ARTICLE
Trend of CD4+ Cell Counts at Diagnosis and Initiation of Highly Active Antiretroviral Therapy (HAART): Korea HIV/AIDS Cohort Study, 1992-2015.
Kim MJ, Chang HH, Kim SI, et al
Infect Chemother. 2017 Jun 1. 
Paper

Outcomes following detection of low level plasma HIV RNA in HIV-infected patients previously virologically suppressed on antiretroviral therapy: a retrospective observational study.
Warren AM, Cheng AC, Watson K, et al
Sex Health. 2017 Apr 27.
Abstract

Can the generic antiretroviral industry support access to a universal antiretroviral regimen?
Amole CD, Middlecote C, Prabhu VR, Kumarasamy N
Curr Opin HIV AIDS. 2017 Apr 24.
Abstract

Universal antiretroviral regimens: thinking beyond one-pill-once-a-day.
Jacobson JM, Flexner C.
Curr Opin HIV AIDS. 2017 Mar 31. .
Abstract

Risks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation.
Matza LS, Chung KC, Kim KJ, et al
Qual Life Res. 2017 Mar 24
Abstract

Long-Acting Antiretrovirals: Where Are We now?
Nyaku AN, Kelly SG, Taiwo BO.
Curr HIV/AIDS Rep. 2017 Mar 16.
Abstract

Changes in Levels of Inflammation Following Antiretroviral Treatment During Early HIV Infection in ACTG A5217.
Macatangay BJ, Yang M, Sun X,
J Acquir Immune Defic Syndr. 2017 Feb 14.
Abstract

Barriers to Universal Prescribing of Antiretroviral Therapy by HIV Care Providers in the United States, 2013-2014.
Weiser J, Brooks JT, Skarbinski J, et al
J Acquir Immune Defic Syndr. 2016 Dec 17
Abstract

Antiretroviral Agents: Looking for the Best Possible Chemotherapeutic Options to Conquer HIV.
Farooq T, Hameed A, Rehman K, et al
Crit Rev Eukaryot Gene Expr. 2016;26(4):363-381.
Abstract

Alveolar bone in human immunodeficiency virus infection: is it changed by long-term antiretroviral therapy?
Nittayananta W, Kanjanaprapas A, Arirachakaran P, et al
Int Dent J. 2016 Nov 18.
Abstract

Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art.
Fiandra L, Capetti A, Sorrentino L, Corsi F
J Neuroimmune Pharmacol. 2016 Nov 10.
Abstract

Marked sex differences in all-cause mortality on antiretroviral therapy in low- and middle-income countries: a systematic review and meta-analysis.
Beckham SW, Beyrer C, Luckow P,
J Int AIDS Soc. 2016 Nov 8;19(1):21106
Abstract

Long-term immune and virological response in HIV-infected patients receiving antiretroviral therapy.
Silveira MP, Silveira CP, Guttier MC, et al.
J Clin Pharm Ther. 2016 Dec;41(6):689-694.
Abstract

Inosine Triphosphate Pyrophosphohydrolase Expression: Decreased in Leukocytes of HIV-Infected Patients Using Combination Antiretroviral Therapy.
Peltenburg NC, Leers MP, Bakker JA,  et al
J Acquir Immune Defic Syndr. 2016 Dec 1;73(4):390-395.
Abstract

Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals.
Nwogu JN, Ma Q, Babalola CP,  et al
AIDS Res Treat. 2016;2016:2587094. Review..
Abstract

Roles and Functions of Social Networks Among Men Who Use Drugs in ART Initiation in Vietnam.
Latkin CA, Smith MK, Ha TV, et al
AIDS Behav. 2016 Nov;20(11):2782-2789
Abstract

FULL-TEXT ARTICLE
Beyond Risk Compensation: Clusters of Antiretroviral Treatment (ART) Users in Sexual Networks Can Modify the Impact of ART on HIV Incidence.
Delva W, Helleringer S.
PLoS One. 2016 Sep 22;11(9):e0163159.
Paper

Long-term body composition changes in antiretroviral-treated HIV-infected individuals.
Grant PM, Kitch D, McComsey GA, et al
AIDS. 2016 Sep 20.
Abstract

New Antiretroviral Treatment for HIV.
Badowski ME, Pérez SE, Biagi M, Littler JA.
Infect Dis Ther. 2016 Aug 18.
Abstract

FULL-TEXT ARTICLE
Factors associated with 10 years of continuous viral load suppression on HAART.
Bello KJ, Mesner O, O'Bryan TA,  et al
BMC Infect Dis. 2016 Jul 22;16:351
Paper

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel.
Günthard HF, Saag MS, Benson CA, et al
JAMA. 2016 Jul 12;316(2):191-210.
Abstract

High antiretroviral coverage and viral suppression prevalence in Japan: an excellent profile for downstream HIV care spectrum
Miyazaki N, Sugiura W, Gatanaga H, et al
Jpn J Infect Dis. 2016 Jun 30.
Abstract

Outcomes of antiretroviral therapy among younger versus older adolescents and adults in an urban clinic, Zimbabwe.
Matyanga CM, Takarinda KC, Owiti P, et al  
Public Health Action. 2016 Jun 21;6(2):97-104
Abstract

FULL-TEXT ARTICLE
Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels
Sörstedt E, Nilsson S, Blaxhult A, et al
BMC Infect Dis. 2016 Jun 21;16(1):305.
Paper

Brief Report: A High Rate of β7+ Gut-Homing Lymphocytes in HIV-Infected Immunological Nonresponders is Associated With Poor CD4 T-Cell Recovery During Suppressive HAART.
Girard A, Vergnon-Miszczycha D, Depincé-Berger AE,  et al
J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):259-65.
Abstract

FULL-TEXT ARTICLE
Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification.
Ananworanich J, Chomont N, Fletcher JL, et al
J Virus Erad. 2015;1(2):116-122.
Paper

Prevalence and distribution of non-AIDS causes of death among HIV-infected individuals receiving antiretroviral therapy- a systematic review and meta-analysis
Farahani M, Mulinder H, Farahani A, Marlink R.
Int J STD AIDS. 2016 Feb 10.
Abstract

Time to Viremia for Patients Taking their First Antiretroviral Regimen and the Subsequent Resistance Profiles.
Crouzat F, Benoit AC, Kovacs C,  et al
HIV Clin Trials. 2016 Jan;17(1):1-11.
Abstract

FULL-TEXT ARTICLE
Dynamic Perturbations of the T-Cell Receptor Repertoire in Chronic HIV Infection and following Antiretroviral Therapy.
Heather JM, Best K, Oakes T,  et al
Front Immunol. 2016 Jan 11;6:644.
Paper

Factors associated with long-term CD4 cell recovery in HIV-infected patients on successful antiretroviral therapy.
Collazos J, Valle-Garay E, Carton JA, et al
HIV Med. 2016 Jan 11.
Abstract

Backbones versus core agents in initial ART regimens: one game, two players.
Llibre JM, Walmsley S, Gatell JM.
J Antimicrob Chemother. 2016 Jan 7.
Abstract

The impact of transient cART in early HIV infection on viral suppression and immunologic response in later treatment.
Pantazis N, Touloumi G, Meyer L, et al
AIDS. 2015 Dec 3.
Abstract

FULL-TEXT ARTICLE
Lipid levels in HIV-positive men receiving anti-retroviral therapy are not associated with copy number variation of reverse cholesterol transport pathway genes.
Marino RB, Kingsley LA, Hussain SK, et al
BMC Res Notes. 2015 Nov 21;8(1):697.
Paper

Medication-Taking Practices of Patients on Antiretroviral HIV Therapy: Control, Power, and Intentionality.
Muessig KE, Panter AT, Mouw MS,  et al.
 AIDS Patient Care STDS. 2015 Nov;29(11):606-616
Abstract

The Impact of Non-Antiretroviral Polypharmacy on the Continuity of Antiretroviral Therapy (ART) Among HIV Patients.
Krentz HB, Gill MJ.
AIDS Patient Care STDS. 2015 Nov 6.
Abstract

FULL-TEXT ARTICLE
Single Tablet Regimen Usage and Efficacy in the Treatment of HIV Infection in Australia.
Armstrong B, Chan DJ, Stewart MJ, Fagan D, Smith D.
AIDS Res Treat. 2015;2015:570316
Paper

Antiretroviral purchasing and prescription practices in Mexico: constraints, challenges and opportunities.
Chaumont C, Bautista-Arredondo S, Calva JJ,  et al 
Salud Publica Mex. 2015;57 Suppl 2:s171-s182.
Abstract

The metabolic and cardiovascular consequences of obesity in persons with HIV on long-term antiretroviral therapy.
Koethe JR, Grome H, Jenkins CA, et al
AIDS. 2015 Sep 28
Abstract

Antiretroviral regimen durability and success in treatment-naïve and treatment-experienced patients by year of treatment initiation, United States, 1996-2011.
Sheth AN, Ofotokun I, Buchacz K, et al
J Acquir Immune Defic Syndr. 2015 Aug 22.
Abstract

Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral Therapy.
Massanella M, Gianella S, Schrier R,  et al
Sci Rep. 2015 Aug 24;5:13179. .
Abstract

The Vancouver Consensus: antiretroviral medicines, medical evidence, and political will.
Beyrer C, Birx DL, Bekker LG,  et al
Lancet. 2015 Aug 8;386(9993):505-7
Abstract

FULL-TEXT ARTICLE
New Highly Active Antiretroviral drugs and generic drugs for the treatment of HIV infection: a budget impact analysis on the Italian National Health Service (Lombardy Region, Northern Italy).
Restelli U, Scolari F, Bonfanti P, et al
BMC Infect Dis. 2015 Aug 11;15(1):323.
Paper

FULL-TEXT ARTICLE
Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada.
Patterson S, Cescon A, Samji H,  et al
BMC Infect Dis. 2015 Jul 17;|
Paper

Mapping chemical structure-activity information of HAART-drug cocktails over complex networks of AIDS epidemiology and socioeconomic data of U.S. counties.
Herrera-Ibatá DM, Pazos A, Orbegozo-Medina RA,  et al
Biosystems. 2015 Apr 24.
Abstract

Effect of Universal Access to Antiretroviral Therapy on HIV/AIDS Mortality in Mexico 1990 - 2011.
Hernández-Ávila JE, Palacio-Mejía LS, Hernández-Romieu A,
J Acquir Immune Defic Syndr. 2015 Apr 13.
Abstract

Post-treatment control of HIV infection.
Conway JM, Perelson AS.
Proc Natl Acad Sci U S A. 2015 Apr 13. pii: 201419162. .
Abstract

FULL-TEXT ARTICLE
Does transient cART started during primary HIV infection undermine the long-term immunologic and virologic response on cART resumption?
Krastinova E, Seng R, Lechenadec J,  et al
BMC Infect Dis. 2015 Apr 10;15(1):178..
Paper

FULL-TEXT ARTICLE
From pills to patients: an evaluation of data sources to determine the number of people living with HIV who are receiving antiretroviral therapy in Germany
Schmidt D, Kollan C, Stoll M,  et al
BMC Public Health. 2015 Mar 17;15(1):252.
Paper

FULL-TEXT ARTICLE
Persistence of Pathological Distribution of NK Cells in HIV-Infected Patients with Prolonged Use of HAART and a Sustained Immune Response
Frias M, Rivero-Juarez A, Gordon A, , et al
PLoS One. 2015 Mar 26;10(3):e0121019.
Paper

Impact of Gender on Long-Term Treatment Outcomes of Highly Active Antiretroviral Therapy (HAART) in the TREAT Asia HIV Observational Database.
Lee MP, Zhou J, Messerschmidt L, Honda M,  et al
AIDS Patient Care STDS. 2015 Mar 16.
Abstract

Subsidized optimal ART for HIV-positive temporary residents of Australia improves virological outcomes: results from the Australian HIV Observational Database Temporary Residents Access Study.
Petoumenos K, Watson J, Whittaker B, et al
J Int AIDS Soc. 2015 Feb 12;18(1):19392.
Paper

Antiretroviral therapy reduces neurodegeneration in HIV infection.
Bryant AK, Ellis RJ, Umlauf A,  et al
AIDS. 2015 Jan 28;29(3):323-30
Abstract

Potential Implication of Residual Viremia in Patients on Effective ART.
Sahu GK.
AIDS Res Hum Retroviruses. 2014 Nov 26
Abstract

FULL-TEXT ARTICLE
Residual Viremia Is Preceding Viral Blips and Persistent Low-Level Viremia in Treated HIV-1 Patients.
Hofstra LM, Mudrikova T, Stam AJ,, et al
PLoS One. 2014 Oct 29;9(10):e110749
Paper

The discovery and development of antiretroviral agents.
Lange JM, Ananworanich J.
Antivir Ther. 2014;19(Suppl 3):5-14.
Abstract

Stimulant Use and Progression to AIDS or Mortality After The Initiation of Highly Active Anti-Retroviral Therapy.
Carrico AW, Shoptaw S, Cox C,  et al
J Acquir Immune Defic Syndr. 2014 Sep 30
Paper

Meeting report: 27th International Conference on Antiviral Research.
Anthony Vere Hodge R.
Antiviral Res. 2014 Sep 10.
Abstract

Treatment Outcomes Among People Living With HIV Who Are Food Insecure and Prescribed Antiretrovirals Taken With Food
Kalichman SC, Washington C, Grebler T,  et al
J Prim Care Community Health. 2014 Sep 8
Abstract

The Demand for Antiretroviral Drugs in the Illicit Marketplace: Implications for HIV Disease Management Among Vulnerable Populations.
Tsuyuki K, Surratt HL, Levi-Minzi MA,  et al
AIDS Behav. 2014 Aug 5.
Paper

FULL-TEXT ARTICLE
Maximizing the benefits of antiretroviral therapy for key affected populations.
Grubb IR, Beckham SW, Kazatchkine M,  et al
J Int AIDS Soc. 2014 Jul 18;17(1):19320
Paper

The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
Di Biagio A, Rusconi S, Marzocchetti A, et al
J Med Virol. 2014 Jul 11.
Abstract

Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure.
Rozera G, Abbate I, Giombini E,  et al
J Antimicrob Chemother. 2014 Jul 10.
Abstract

FULL-TEXT PDF ARTICLE
Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study.
Estébanez M, Stella-Ascariz N, Mingorance J, et al
BMC Infect Dis. 2014 Jul 10;14(1):379
Paper

Addressing the Achilles' Heel in the HIV Care Continuum for the Success of a Test-and-Treat Strategy to Achieve an AIDS-Free Generation.
Nachega JB, Uthman OA, Del Rio C, et al
Clin Infect Dis. 2014 Jul 1;59 Suppl 1:S21-7.
Abstract

Leveraging HIV Treatment to End AIDS, Stop New HIV Infections, and Avoid the Cost of Inaction.
Sidibé M, Zuniga JM, Montaner J.
Clin Infect Dis. 2014 Jul 1;59 Suppl 1:S3-6
Abstract

CROI 2014: advances in antiretroviral therapy.
Taylor BS, Shalev N, Wilkin TJ.
Top Antivir Med. 2014 May;22(2):616-31."'
Paper

"Old Dogs with New Tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets.
Kang D, Song Y, Chen W, et al
Mol Biosyst. 2014 May 20.
Abstract

FULL-TEXT ARTICLE
HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality.
Serrano-Villar S, Sainz T, Lee SA,  et al
PLoS Pathog. 2014 May 15
Paper

Impact of risk factors for specific causes death in the first and subsequent years of ART among HIV-infected patients.
Ingle SM, May MT, Gill MJ, et al  for the Antiretroviral Therapy Cohort Collaboration.
Clin Infect Dis. 2014 Apr 24.
Abstract

The Evolution of Three Decades of Antiretroviral Therapy: Challenges, Triumphs and the Promise of the Future.
Tseng A, Seet J, Phillips EJ.
Br J Clin Pharmacol. 2014 Apr 15.
Abstract

Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence.
Yanik EL, Napravnik S, Cole SR,  et al
AIDS. 2014 Apr 24;28(7):979-87.
Abstract

Optimal strategies for monitoring response to antiretroviral therapy in HIV-infected adults, adolescents, children and pregnant women: a systematic review.
Tucker JD, Bien CH, Easterbrook PJ,  et al
AIDS. 2014 Mar;28 Suppl 2:S151-60.
Abstract

FULL-TEXT ARTICLE
CD4 Counts and Viral Loads of Newly Diagnosed HIV-Infected Individuals: Implications for Treatment as Prevention.
Govender S, Otwombe K, Essien T, et al
PLoS One. 2014 Mar 4;9(3):e90754. 
Paper

FULL-TEXT ARTICLE
Association between nutritional status and the immune response in HIV + patients under HAART: protocol for a systematic review.
Sicotte M, Langlois EV, Aho J,  et al
Syst Rev. 2014 Feb 10;3(1):9.
Paper

FULL-TEXT ARTICLE
Race/ethnicity and HAART initiation in a military HIV infected cohort.
Johnson EN, Roediger MP, Landrum ML,  et al
AIDS Res Ther. 2014 Jan 24;11(1):10
Paper

Sex Differences in HIV Outcomes in the HAART Era: A Systematic Review.
Castilho JL, Melekhin VV, Sterling TR.
AIDS Res Hum Retroviruses. 2014 Jan 9
Abstract

New Approaches to Antiretroviral Drug Delivery: Challenges and Opportunities Associated with the Use of Long-Acting Injectable Agents.
Boffito M, Jackson A, Owen A, Becker S.
Drugs. 2013 Dec 11..
Abstract

Discontinuation of antiretroviral therapy among adults receiving HIV care in the United States.
Hughes AJ, Mattson CL, Scheer S,  et al
J Acquir Immune Defic Syndr. 2013 Dec 8.
Abstract

FULL-TEXT ARTICLE
Modelling the Strategic Use of Antiretroviral Therapy for the Treatment and Prevention of HIV.
Ford N, Hirnschall G.
PLoS Med. 2013 Oct;10(10):e1001535
Paper

Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?
Cohen MS, Smith MK, Muessig KE, et al
Lancet. 2013 Oct 18.| .
Abstract

The antiretroviral drug pipeline: prospects and implications for future treatment research.
Flexner C, Saag M.
Curr Opin HIV AIDS. 2013 Oct 4.
Abstract

Long-acting injectable antiretrovirals for HIV treatment and prevention.
Spreen WR, Margolis DA, Pottage JC Jr.
Curr Opin HIV AIDS. 2013 Oct 4
Abstract

Single-tablet regimens in hiv: does it really make a difference?
Aldir I, Horta A, Serrado M.
Curr Med Res Opin. 2013 Sep 16.
Abstract

Separate Goals, Converging Priorities: On the Ethics of Treatment as Prevention.
Ostmann F, Saenz C.
Dev World Bioeth. 2013 Jun 25
Abstract

A Side Door Into Care Cascade for HIV-Infected Patients?
Hallett TB, Eaton JW.
J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S228-32. d.
Abstract

An Expanded Behavioral Paradigm for Prevention and Treatment of HIV-1 Infection.
Coates TJ.
J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S179-82.
Abstract